Life Sciences as a Long-Cycle Asset: A Family Office Perspective Tickets, Thursday, Mar 19 from 3 pm to 5 pm

Overview

While life sciences is often viewed through a technical or philanthropic lens, it actually offers a unique strategic fit for family offices.

In practice, it is a long-cycle, stage-based asset class that mirrors the capital philosophy of the resources sector. This 2 hour session is designed to equip Principals, CIOs, and Investment Leads with clear decision frameworks to translate clinical and regulatory milestones into the familiar language of staged deployment, optionality, and risk mitigation. The speakers at this event will include Kerri Lee Sinclair, Steve Burnell, Paul Anderson, Brian Leedman and Helen Mutimer.

The session will feature:

Strategic Framing: Translating life sciences into the "capital language" of WA investors (milestones, staging, and downside protection).
Expert Panel & Fireside Chat: Insights from Family Office perspectives and industry leaders on pacing capital and separating impact from return.
Risk & Governance Reality Check: A deep dive into where non-specialist capital underperforms and how disciplined capital builds conviction.

The session will take place in the Wattle Room and conclude with a networking opportunity to discuss portfolio fit and governance with peers. Following this event, AusBiotech will also be hosting the WA BioCheers at The Westin; we would be delighted to have you join us. Please be advised that this event will require a separate registration.

Please note: This event is designed for investors and family office principals. It is not a forum for founders seeking capital or technical/scientific deep dives.

Terms and Conditions

This registration is strictly non-transferable. Access is granted only to the named registrant; tickets may not be reassigned or shared.

By registering for this event you agree to the terms and conditions set out by AusBiotech.

While life sciences is often viewed through a technical or philanthropic lens, it actually offers a unique strategic fit for family offices.

In practice, it is a long-cycle, stage-based asset class that mirrors the capital philosophy of the resources sector. This 2 hour session is designed to equip Principals, CIOs, and Investment Leads with clear decision frameworks to translate clinical and regulatory milestones into the familiar language of staged deployment, optionality, and risk mitigation. The speakers at this event will include Kerri Lee Sinclair, Steve Burnell, Paul Anderson, Brian Leedman and Helen Mutimer.

The session will feature:

Strategic Framing: Translating life sciences into the "capital language" of WA investors (milestones, staging, and downside protection).
Expert Panel & Fireside Chat: Insights from Family Office perspectives and industry leaders on pacing capital and separating impact from return.
Risk & Governance Reality Check: A deep dive into where non-specialist capital underperforms and how disciplined capital builds conviction.

The session will take place in the Wattle Room and conclude with a networking opportunity to discuss portfolio fit and governance with peers. Following this event, AusBiotech will also be hosting the WA BioCheers at The Westin; we would be delighted to have you join us. Please be advised that this event will require a separate registration.

Please note: This event is designed for investors and family office principals. It is not a forum for founders seeking capital or technical/scientific deep dives.